Whereabouts failures: Jamaica's 2026 anti-doping cases

Carey McLeod: a two-year ban without a positive test

One of Jamaica's most significant anti-doping cases of 2026 involved no drug at all. On 1 June the Athletics Integrity Unit (AIU), World Athletics' independent integrity body, announced that Carey McLeod, the two-time national long jump champion and 2024 World Indoor bronze medallist, had accepted a two-year ban for a whereabouts violation under Article 2.4 of the World Athletics Anti-Doping Rules¹²³.

The three failures came within twelve months. On 30 June 2025 a Doping Control Officer could not find him at a St Andrew address during his 5:00 to 6:00 a.m. testing window. His whereabouts filing then placed him in Arkansas while he was preparing to compete in Budapest on 12 August 2025. On 1 May 2026 an officer could not locate him at a Clarendon address during his window²³. He did not respond to requests for explanations about the first two failures or seek an administrative review; his attorney told the AIU on 26 May that he would not contest the case and wanted it to "move forward urgently", and he signed an admission on 28 May²³. He is ineligible from 28 May 2026 to 27 May 2028, his results from 1 May 2026 are disqualified, and he forfeits medals, points and prize money from that date. The Jamaica Anti-Doping Commission (JADCO) and the World Anti-Doping Agency (WADA) can still appeal to the Court of Arbitration for Sport¹²³.

Omar McLeod: a reported case, no decision

In September 2026 a second, more prominent name surfaced. Citing The Gleaner, Caribbean National Weekly reported on 15 September that Omar McLeod, the 2016 Olympic and 2017 world 110 m hurdles champion and national record holder at 12.90 seconds, reportedly had one missed test and two filing failures between 2025 and 2026, the missed test reportedly in Europe, where he had been training. JADCO had been advised of the alleged violation; the Jamaica Athletics Administrative Association had not confirmed notification, and McLeod could not be reached for comment⁴. EssentiallySports, citing Jamaican journalist Kayon Raynor and TVJ sources, described it as a potential sanction, not a confirmed suspension⁵. He had not raced since 17 June 2025⁴. No decision had been reported when this article was written.

What the whereabouts rules require

Athletes in a registered testing pool must file quarterly whereabouts information, including home address, overnight accommodation, regular activities and competition schedule, and must name a daily one-hour window when they can be tested out of competition⁴. Missed tests and filing failures each count, and three in twelve months is a violation that can bring up to two years' ineligibility²⁴. The Jamaica Observer's editorial page made the point in 2023, after 400 m runner Christopher Taylor was charged under the rule on evading, refusing or failing to submit to sample collection after officers found he was not at the location on his whereabouts form: athletes must watch for the procedural pitfalls. Then JADCO Chairman Alexander Williams urged athletes not to "be wishy-washy" about anti-doping procedures⁸.

JADCO's legal framework

Testing in Jamaica rests on the Anti-Doping in Sport Act, 2014 (Act 22 of 2014), in force since 1 January 2015, which repealed the 2008 Act, established JADCO under section 5 and an Anti-Doping Appeal Tribunal under section 17, and adopts the World Anti-Doping Code's definitions of violations and consequences, including disqualification, ineligibility and provisional suspension⁶. Crucially for physicians, the Act defines "Athlete Support Personnel" to include any "medical, paramedical Personnel" working with, treating or assisting an athlete⁶. When the revised Code took effect in 2015, the Jamaica Information Service noted that it allows sanctions against support personnel and others in an athlete's entourage who break the rules or help others breach them⁷.

Why peptides matter to Jamaican team doctors

The 2026 WADA Prohibited List bans at all times, in and out of competition, any non-approved substance (S0), and names BPC-157 as an example. Under S2 it lists growth hormone fragments such as AOD-9604, GHRH analogues including CJC-1295, sermorelin and tesamorelin, growth hormone secretagogues including ipamorelin and ibutamoren, the GH-releasing peptides GHRP-1 to GHRP-6, and thymosin-β4 derivatives such as TB-500⁹. Unknowing ingestion is no defence on its own: in an AIU case resolved in 2026 that could lift Jamaica's Shanoya Douglas to a world under-20 silver medal, the winner who tested positive for metabolites of GW501516 was found to have ingested it unknowingly and still served a ban, with part suspended for substantial assistance¹¹. The clinical evidence for many of these peptides is thin: a systematic review of BPC-157 found 35 preclinical studies, one clinical study and no clinical safety data¹⁰.